Skip to Content

Procter & Gamble Earnings: Sales and Margins Pop, but Competitive and Macro Headwinds Loom

We do not expect significant revisions to our forecast, although we’ll likely tick up our fair value estimate for P&G stock.

The Procter & Gamble Co., headquarters building is shown in Cincinnati

Key Morningstar Metrics for Procter & Gamble

What We Thought of Procter & Gamble’s Earnings

We think the main question heading into Procter & Gamble’s PG first quarter was how volumes fared against increased competition and a cash-stretched consumer. In our view, the strength of the firm’s portfolio and its standing with retailers was evident, as organic sales jumped 7%. Impressively, volumes edged down just 1% on a 7% benefit from higher prices.

Despite weakness in China (around 10% of sales, down 6%), sales on its home turf (about half of sales) shot up 7%. Private label is making inroads, but promotions lag pre-pandemic levels, and management suggested its market share position is generally holding in most categories and geographies. We believe P&G should weather any impending challenges, given that its portfolio is weighted to daily-use essential categories that consumers are unlikely to abandon in any economic climate.

From a profitability perspective, higher prices (a 330-basis-point benefit), a favorable drop in commodity costs (160 basis points), and productivity savings (150 basis points) that were only partially offset by reinvestments in products and packaging drove a whopping 460-basis-point surge in gross margin to 52%. We anticipate the profit boost from pricing and the downdraft in commodities will fade over the next few quarters. However, we expect P&G will continue to invest to support its competitive edge for the long term. Our forecast calls for P&G to direct around 13% of sales to research, development, and marketing on average annually over our explicit forecast.

When taken together, management’s full-year outlook for 4%-5% organic sales growth against 6%-9% EPS growth is unchanged. Thus, we do not expect to make significant revisions to our forecast, although we’ll likely tick up our $136 fair value estimate by $1-$2 per share for time value. After a low-single-digit percentage bump, shares aren’t a bargain, but we suggest investors keep an eye on this wide-moat name for a potential downdraft in the stock price stemming from industry angst.

Procter & Gamble Stock Price

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Erin Lash

Sector Director
More from Author

Erin Lash, CFA, is director of consumer sector equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. In addition to leading the sector team, Lash covers packaged food and household and personal care companies.

Before joining Morningstar in 2006, she spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance.

Lash holds a bachelor’s degree in finance from Bradley University and a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. She also holds the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

Sponsor Center